Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Jun 2020
Historique:
received: 21 04 2020
revised: 29 05 2020
accepted: 31 05 2020
entrez: 6 6 2020
pubmed: 6 6 2020
medline: 31 3 2021
Statut: epublish

Résumé

Interactions between tumor cells and tumor-associated macrophages (TAMs) are critical for glioblastoma progression. The TAMs represent up to 30% of the glioblastoma mass. The role of TAMs in tumor progression and in the mechanisms underlying tumor growth remain unclear. Using an in vitro model resembling the crosstalk between macrophages and glioblastoma cells, we show that glioblastoma-derived exosomes (GBex) reprogram M1 (mediate pro-inflammatory function) and M2 (mediate anti-inflammatory function) macrophages, converting M1 into TAMs and augmenting pro-tumor functions of M2 macrophages. In turn, these GBex-reprogrammed TAMs, produce exosomes decorated by immunosuppressive and tumor-growth promoting proteins. TAM-derived exosomes disseminate these proteins in the tumor microenvironment (TME) promoting tumor cell migration and proliferation. Mechanisms underlying the promotion of glioblastoma growth involved Arginase-1+ exosomes produced by the reprogrammed TAMs. A selective Arginase-1 inhibitor, nor-NOHA reversed growth-promoting effects of Arginase-1 carried by TAM-derived exosomes. The data suggest that GBex-reprogrammed Arginase-1+ TAMs emerge as a major source of exosomes promoting tumor growth and as a potential therapeutic target in glioblastoma.

Identifiants

pubmed: 32498400
pii: ijms21113990
doi: 10.3390/ijms21113990
pmc: PMC7312363
pii:
doi:

Substances chimiques

Immunosuppressive Agents 0
ARG1 protein, human EC 3.5.3.1
Arginase EC 3.5.3.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : RO-I CA168628
Pays : United States
Organisme : NIH HHS
ID : P306A047904
Pays : United States
Organisme : Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften
ID : LPDS 2017-12

Références

Cancer Med. 2019 Aug;8(10):4709-4721
pubmed: 31222971
Nat Commun. 2019 Jul 5;10(1):3000
pubmed: 31278254
Acta Neuropathol. 2014 Sep;128(3):347-62
pubmed: 24722970
Int J Mol Sci. 2018 Mar 27;19(4):
pubmed: 29584702
Mol Neurobiol. 2019 May;56(5):3260-3279
pubmed: 30117104
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
Br J Pharmacol. 2009 Oct;158(3):638-51
pubmed: 19764983
Cancer Lett. 2017 May 1;393:60-67
pubmed: 28216373
Mol Neurobiol. 2018 Aug;55(8):6927-6938
pubmed: 29363044
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Pathol. 2013 Jan;229(2):176-85
pubmed: 23096265
J Cancer. 2019 Jun 2;10(13):2892-2906
pubmed: 31281466
Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2652-2662
pubmed: 28713019
Lancet. 2018 Aug 4;392(10145):432-446
pubmed: 30060998
Clin Cancer Res. 2019 Jul 15;25(14):4202-4210
pubmed: 30804019
J Exp Clin Cancer Res. 2019 Jul 15;38(1):310
pubmed: 31307515
Microb Pathog. 2017 Oct;111:132-138
pubmed: 28843722
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Curr Oncol Rep. 2019 Mar 5;21(4):30
pubmed: 30835007
J Cell Biochem. 2015 May;116(5):721-9
pubmed: 25546398
J Exp Clin Cancer Res. 2017 Apr 13;36(1):53
pubmed: 28407783
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389898
Adv Med Sci. 2019 Mar;64(1):104-110
pubmed: 30605863
Curr Protoc Immunol. 2019 Dec;127(1):e91
pubmed: 31763776
Immunol Rev. 2014 Nov;262(1):36-55
pubmed: 25319326
Semin Oncol Nurs. 2018 Dec;34(5):486-493
pubmed: 30392759

Auteurs

Juliana H Azambuja (JH)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, Brazil.

Nils Ludwig (N)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.

Saigopalakrishna S Yerneni (SS)

Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA.

Elizandra Braganhol (E)

Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, Brazil.

Theresa L Whiteside (TL)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Departments of Immunology and Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH